Summary & Overview
CPT 55708: Transrectal Ultrasound–Guided Prostate Biopsy with MRI–US Fusion
CPT code 55708 represents a transrectal ultrasound–guided prostate biopsy that combines systematic sextant sampling with MRI–ultrasound fusion to target a suspicious lesion. This composite approach blends standard mapped sampling with precision targeting, improving lesion localization and diagnostic yield for suspected prostate cancer. Nationally, the code is relevant as image-fusion biopsy techniques become more widely available and as payers assess medical necessity and coverage for advanced diagnostic procedures.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for the procedure, the typical sites of service, and how this code is positioned relative to other prostate biopsy services. The publication presents benchmarks for utilization and reimbursement where available, summaries of payer coverage considerations and coding guidance, and notes on clinical implications for diagnostic accuracy and workflow. Data not available in the input is explicitly identified where applicable. The summary equips billing managers, revenue cycle staff, and policy analysts with the information needed to understand service classification and payer relevance for CPT code 55708.
Billing Code Overview
CPT code 55708 describes a transrectal ultrasound–guided prostate biopsy with systematic sampling of sextants combined with MRI–ultrasound fusion targeting of a suspicious lesion. The service uses standard mapped sampling (sextant approach) and adds image-fusion targeting to obtain cores from a lesion identified on prior MRI.
-
Service type: Image-guided diagnostic prostate biopsy combining systematic and targeted sampling
-
Typical site of service: Outpatient ambulatory surgery center or hospital outpatient department, commonly performed in urology clinics with ultrasound and MRI-fusion capability
Clinical & Coding Specifications
Clinical Context
A typical patient is a 62-year-old man with an elevated serum prostate-specific antigen (PSA) of 8.2 ng/mL and a suspicious lesion identified on prostate multiparametric MRI. He has either a prior negative TRUS biopsy with persistent clinical concern or a new abnormal digital rectal exam. The urology team schedules a transrectal ultrasound–guided prostate biopsy with MRI–ultrasound fusion to sample standard mapped areas (sextants) and to target the MRI-visible lesion.
The clinical workflow begins with pre-procedure counseling and informed consent, review of anticoagulation status, and prophylactic antibiotics per facility protocol. On the day of service the patient is positioned in left lateral decubitus or lithotomy. A transrectal ultrasound probe is used to map the prostate and guide systematic sextant sampling. MRI images are fused with real-time ultrasound to localize and target the suspicious lesion(s). The provider obtains multiple cores from each sextant and additional targeted cores from the fused MRI lesion. Specimens are labeled and sent to pathology. Post-procedure monitoring includes observation for bleeding, urinary retention, infection, and post-biopsy instructions with follow-up for pathology results.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing only the physician professional portion separate from technical component for ultrasound-guided biopsy when applicable. |